Crescent Capital BDC (NASDAQ:CCAP – Get Free Report) posted its earnings results on Wednesday. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.41 by $0.01, Zacks reports. The firm had revenue of ($6.84) million for the quarter, compared to analysts’ expectations of $39.58 million. Crescent Capital BDC had a net margin of 9.26% and a return on equity of 9.20%.
Crescent Capital BDC Stock Performance
Shares of Crescent Capital BDC stock traded down $0.80 during trading hours on Friday, reaching $11.20. The company had a trading volume of 674,570 shares, compared to its average volume of 206,608. The firm has a market cap of $413.88 million, a PE ratio of 27.30 and a beta of 0.59. Crescent Capital BDC has a one year low of $11.03 and a one year high of $16.03. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.22 and a quick ratio of 1.22. The business has a fifty day simple moving average of $12.98 and a 200 day simple moving average of $13.78.
Crescent Capital BDC Dividend Announcement
The firm also recently announced a special dividend, which will be paid on Tuesday, December 15th. Shareholders of record on Monday, November 30th will be issued a dividend of $0.03 per share. The ex-dividend date of this dividend is Monday, November 30th. Crescent Capital BDC’s payout ratio is presently 409.76%.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
A number of analysts recently commented on CCAP shares. Wells Fargo & Company dropped their price target on Crescent Capital BDC from $13.00 to $12.00 and set an “equal weight” rating on the stock in a report on Friday. B. Riley Financial reiterated a “neutral” rating on shares of Crescent Capital BDC in a research note on Friday. Keefe, Bruyette & Woods cut their price target on shares of Crescent Capital BDC from $15.50 to $15.00 and set an “outperform” rating on the stock in a report on Thursday, April 16th. Zacks Research upgraded shares of Crescent Capital BDC from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 10th. Finally, Oppenheimer cut shares of Crescent Capital BDC from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $19.00 to $16.00 in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, Crescent Capital BDC currently has an average rating of “Moderate Buy” and a consensus price target of $14.70.
Check Out Our Latest Analysis on CCAP
About Crescent Capital BDC
Crescent Capital BDC, Inc is a closed-end, externally managed business development company that provides flexible financing solutions to middle market companies in the United States. Trading on the Nasdaq under the ticker CCAP, the firm offers investors exposure to a diversified portfolio of debt and equity instruments, targeting businesses with attractive risk-adjusted return profiles. Its primary objective is to generate current income through interest payments and potential capital appreciation via selective equity co-investments.
The company’s investment strategy emphasizes senior secured loans, unsecured second-lien loans, mezzanine debt, as well as preferred and common equity co-investments.
Featured Stories
- Five stocks we like better than Crescent Capital BDC
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Crescent Capital BDC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescent Capital BDC and related companies with MarketBeat.com's FREE daily email newsletter.
